United Therapeutics Secures $175M Payment and YUTREPIA Clarity in Liquidia Settlement
UTHR sits 33% above its 52-week low of $409.07.
Summary
United Therapeutics will receive a $175 million net payment from Liquidia within 30 business days as part of a $380.7 million antitrust settlement. The settlement also resolves the YUTREPIA label dispute: the inhaled dry-powder treprostinil remains available for PAH, but the PH-ILD indication is removed and will not be promoted. This follows the October 1 federal court ruling that Liquidia induces infringement of UTHR's inhaled treprostinil patent. The FDA acceptances of the ralinepag NDA and nebulized Tyvaso sNDA were previously reported in August and September; today's news adds the financial terms and product label clarity. The $175 million payment is material relative to UTHR's $23 billion market cap and removes a key overhang on YUTREPIA's commercial positioning.
Updates
· SEC 8-K — Liquidia will pay United Therapeutics $330.4 million total: $185 million within 30 business days and $145.4 million in two $72.7 million installments due February 1 and April 30, 2027.
At the time of this announcement, UTHR was trading at $545.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3B. The 52-week trading range was $409.07 to $609.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.